British patients test world’s first personalised mRNA jab for melanoma

Moderna and MSD are researching how their therapy could treat a wide range of cancers.

The world’s first personalised mRNA cancer jab for melanoma – which also has the potential to stop lung, bladder and kidney cancer – is being tested in Britishpatients.

The “gamechanger” jab, which offers hope of a cure, is custom-built for each person in just a few weeks.

It works by telling the body to hunt down cancer cells and prevent the deadly disease from coming back.

A stage 2 trial of the jab, involving pharma firms Moderna and MSD, found it dramatically reduced the risk of the cancer returning in melanoma patients.

Now a final phase 3 trial has been launched, led by University College London Hospitals NHS Foundation Trust (UCLH).